HK1207981A1 - Methods of treating and preventing staphylococcus aureus infections and associated conditions - Google Patents

Methods of treating and preventing staphylococcus aureus infections and associated conditions Download PDF

Info

Publication number
HK1207981A1
HK1207981A1 HK15108668.7A HK15108668A HK1207981A1 HK 1207981 A1 HK1207981 A1 HK 1207981A1 HK 15108668 A HK15108668 A HK 15108668A HK 1207981 A1 HK1207981 A1 HK 1207981A1
Authority
HK
Hong Kong
Prior art keywords
methods
staphylococcus aureus
treating
aureus infection
associated conditions
Prior art date
Application number
HK15108668.7A
Other languages
English (en)
Chinese (zh)
Inventor
Victor J. Torres
Ashley L. Dumont
Original Assignee
New York University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University filed Critical New York University
Publication of HK1207981A1 publication Critical patent/HK1207981A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
HK15108668.7A 2012-05-02 2013-03-15 Methods of treating and preventing staphylococcus aureus infections and associated conditions HK1207981A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261641543P 2012-05-02 2012-05-02
US61/641,543 2012-05-02
PCT/US2013/032436 WO2013165613A1 (en) 2012-05-02 2013-03-15 Methods of treating and preventing staphylococcus aureus infections and associated conditions

Publications (1)

Publication Number Publication Date
HK1207981A1 true HK1207981A1 (en) 2016-02-19

Family

ID=49514732

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108668.7A HK1207981A1 (en) 2012-05-02 2013-03-15 Methods of treating and preventing staphylococcus aureus infections and associated conditions

Country Status (9)

Country Link
US (1) US9657103B2 (enExample)
EP (1) EP2844287A4 (enExample)
JP (1) JP2015517463A (enExample)
CN (1) CN104428000A (enExample)
AU (1) AU2013257161B2 (enExample)
CA (1) CA2871152A1 (enExample)
HK (1) HK1207981A1 (enExample)
IL (1) IL235284A0 (enExample)
WO (1) WO2013165613A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014270598B2 (en) * 2013-05-21 2018-09-20 Arsanis Biosciences Gmbh Generation of highly potent antibodies neutralizing the LukGH (LukAB) toxin of Staphylococcus aureus
JP2018517708A (ja) 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
CN108135961A (zh) * 2015-06-12 2018-06-08 台湾基督长老教会马偕医疗财团法人马偕纪念医院 调控免疫反应的方法及多肽
CN110913883A (zh) * 2017-06-13 2020-03-24 综合生物治疗疫苗公司 包含金黄色葡萄球菌杀白细胞素luka和lukb来源的多肽的免疫原性组合物
US12291562B2 (en) 2019-04-01 2025-05-06 Rush University Medical Center Reagents and assays using modified integrin domains
CN114437187B (zh) * 2022-02-09 2023-06-20 淮北师范大学 一种细菌素Bacin A4及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5602299A (en) 1992-09-23 1997-02-11 Mount Sinai School Of Medicine Of The City University Of New York Transgenic animal models for neurodegenerative disease
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
US20030162956A1 (en) * 1997-04-07 2003-08-28 Human Genome Sciences, Inc. Leukocyte regulatory factors 1 and 2
JP2004504827A (ja) * 2000-07-31 2004-02-19 ザ　ジェネラル　ホスピタル　コーポレーション 高親和性インテグリンポリペプチドおよびその使用方法
US7323552B2 (en) * 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
WO2004020601A2 (en) * 2002-08-28 2004-03-11 University Of Florida Neurogenesis from hepatic stem cells
JP2006094701A (ja) * 2002-09-17 2006-04-13 Chugai Pharmaceut Co Ltd ７ｆ４遺伝子トランスジェニック動物
JP4897690B2 (ja) * 2004-10-12 2012-03-14 ジェネンテック， インコーポレイテッド 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド
WO2006086500A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Compositions and methods for treating vascular, autoimmune and inflammatory diseases
JP2008537478A (ja) * 2005-02-24 2008-09-18 ザ・スクリプス・リサーチ・インステイチユート 単離骨髄球様骨髄細胞集団及びそれを用いた治療方法
JP5250810B2 (ja) * 2006-05-31 2013-07-31 公益財団法人ヒューマンサイエンス振興財団 ユートロフィン遺伝子発現増強物質のスクリーニング
JP2008220174A (ja) * 2007-03-08 2008-09-25 Tokyoto Igaku Kenkyu Kiko 変異型βシヌクレインとαシヌクレインとを共発現する形質転換細胞及びトランスジェニック非ヒト動物
US20100310665A1 (en) 2007-10-25 2010-12-09 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
EP4219560A3 (en) * 2010-02-18 2023-08-23 The Regents of The University of California Integrin alpha v beta 8 neutralizing antibody
HUE058787T2 (hu) * 2010-05-05 2022-09-28 Univ New York Staphylococcus aureus leukocidinek, terápiás készítmények és azok felhasználása
US9023876B2 (en) * 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
MX343589B (es) * 2011-06-19 2016-11-11 Univ New York Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida.
CN103717234A (zh) 2011-06-19 2014-04-09 纽约大学 治疗和预防金黄色葡萄球菌感染及相关病状的方法

Also Published As

Publication number Publication date
AU2013257161B2 (en) 2017-11-09
AU2013257161A1 (en) 2014-11-20
WO2013165613A1 (en) 2013-11-07
CA2871152A1 (en) 2013-11-07
US20150132310A1 (en) 2015-05-14
IL235284A0 (en) 2014-12-31
JP2015517463A (ja) 2015-06-22
EP2844287A4 (en) 2016-01-27
CN104428000A (zh) 2015-03-18
EP2844287A1 (en) 2015-03-11
US9657103B2 (en) 2017-05-23

Similar Documents

Publication Publication Date Title
HK1223093A1 (zh) 杀真菌组合物
WO2014031928A3 (en) Heterocyclic modulators of hif activity for treatment of disease
PH12017500834A1 (en) Methods and formulations for treating vascular eye diseases
HK1226063A1 (zh) 选择性grp94抑制剂和其用途
GB2480772B (en) Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
WO2012149549A3 (en) Bacillus bacteria for use in treating and preventing infection in aquatic animals
PH12014500767A1 (en) Compositions for the treatment of dry eye
WO2014031933A3 (en) Heterocyclic modulators of hif activity for treatment of disease
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
HK1207981A1 (en) Methods of treating and preventing staphylococcus aureus infections and associated conditions
UA118610C2 (uk) Спіроциклічні інгібітори катепсину c
WO2014031936A3 (en) Heterocyclic modulators of hif activity for treatment of disease
PH12013502135A1 (en) Antimicrobial compounds and methods of making and using the same
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
UA114528C2 (uk) Комбінації активних сполук, що містять карбоксамідні похідні та засіб біологічної боротьби
PH12014501693A1 (en) Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof
NZ702087A (en) Pharmaceutical compositions and treatment of mastitis
EP3294761A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF UROPATHOGEN E. COLI
TN2015000255A1 (fr) Chitine ou ses derives pour la prevention et/ou le traitement de parasitoses
EA201500913A1 (ru) Противомикробные соединения и способы их получения и применения
EP2964750A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND / OR PREVENTING TYPE-1 DIABETES
EP3341034A4 (en) ANTIMICROBIAL AND ENZYME-INHIBITING ZINC OXIDE NANOPARTICLES
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
EP2948219A4 (en) TARGETING THE STEROIDOGENIC PATH TO TREAT AND / OR PREVENT ALLERGIC DISEASES
EP3065548A4 (en) Fibrosis inhibiting compounds and methods of use thereof in the prevention or treatment of fibrosing diseases